Publications by authors named "A Edet-Sanson"
Article Synopsis
- Nuclear medicine continues to play a vital role in treating thyroid cancers, specifically through the use of iodine-131 (RAI) for differentiated thyroid cancer (DTC) and post-therapeutic scintigraphy to assess treatment response.
- For challenging cases where RAI isn't effective, FDG PET imaging aids in diagnosis and prognosis, particularly for less than 5% of those with refractory disease and for aggressive anaplastic thyroid cancer.
- Emerging theranostic strategies are being developed using various radiopharmaceuticals and imaging methods like 18F-DOPA, PSMA, and FAP, highlighting a shift from traditional treatments towards more personalized approaches in managing thyroid cancer.
Patients with metastatic castration-resistant prostate cancer usually have lymph nodes and bone metastasis. We present a rare case of a 51-year-old patient with metastatic castration-resistant prostate cancer who complained of left truncated sciatica and diffuse bone pain and who was referred for 177 Lu-prostate-specific membrane antigen (PSMA) screening. Pretreatment 68 Ga-PSMA showed left sciatic nerve and multiple bone uptake.
View Article and Find Full Text PDFRadio-iodine refractory (RAI-R) differentiated thyroid cancer (DTC) is a rare disease with a poor prognosis and limited therapeutic resources. Therefore, identifying prognostic factors is essential in order to select patients who could benefit from an early start of treatment. The aim of this study is to identify positron emission tomography with 18F-fluorodeoxyglucose with integrated computed tomography (18F-FDG-PET/CT) parameters to predict overall survival (OS) in patients with RAI-R DTC.
View Article and Find Full Text PDF